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Abstract
Background: Two current leading malaria blood-stage vaccine candidate antigens for Plasmodium falciparum, the C-
terminal region of merozoite surface protein 1 (MSP119) and apical membrane antigen 1 (AMA1), have been prioritized
because of outstanding protective efficacies achieved in a rodent malaria Plasmodium yoelii model. However, P. falciparum
vaccines based on these antigens have had disappointing outcomes in clinical trials. Discrepancies in the vaccine efficacies
observed between the P. yoelii model and human clinical trials still remain problematic.
Methodology and Results: In this study, we assessed the protective efficacies of a series of MSP119- and AMA1-based
vaccines using the P. berghei rodent malarial parasite and its transgenic models. Immunization of mice with a baculoviral-
based vaccine (BBV) expressing P. falciparum MSP119 induced high titers of PfMSP119-specific antibodies that strongly
reacted with P. falciparum blood-stage parasites. However, no protection was achieved following lethal challenge with
transgenic P. berghei expressing PfMSP119 in place of native PbMSP119. Similarly, neither P. berghei MSP119- nor AMA1-BBV
was effective against P. berghei. In contrast, immunization with P. yoelii MSP119- and AMA1-BBVs provided 100% and 40%
protection, respectively, against P. yoelii lethal challenge. Mice that naturally acquired sterile immunity against P. berghei
became cross-resistant to P. yoelii, but not vice versa.
Conclusion: This is the first study to address blood-stage vaccine efficacies using both P. berghei and P. yoelii models at the
same time. P. berghei completely circumvents immune responses induced by MSP119- and AMA1-based vaccines,
suggesting that P. berghei possesses additional molecules and/or mechanisms that circumvent the host’s immune
responses to MSP119 and AMA1, which are lacking in P. yoelii. Although it is not known whether P. falciparum shares these
escape mechanisms with P. berghei, P. berghei and its transgenic models may have potential as useful tools for identifying
and evaluating new blood-stage vaccine candidate antigens for P. falciparum.
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Introduction
Malaria is an enormous public health problem worldwide and
kills one to two million people every year, mostly children residing
in Africa. Clearly, an effective vaccine for the control of malaria is
urgently needed. The selection of protein antigens for malaria
vaccine development has been hampered by the lack of a reliable
and readily accessible challenge system for Plasmodium falciparum.
Accordingly, much attention has focused on the study of
laboratory rodents infected by murine malaria parasite species,
most notably P. yoelii and P. berghei. Although not perfect models
for human infection, these systems have proved useful, and
important advances in our understanding of the principles of
vaccine design have followed their use. For blood-stage vaccine
development, in particular, the P. yoelii-murine model has greatly
contributed to the evaluation of protective efficacies of blood-stage
antigens prior to human clinical trials. Based on the P. yoelii model,
many asexual blood-stage candidate antigens have been identified
for malaria vaccine development. Of these, two leading malaria
blood-stage vaccine candidates, merozoite surface protein 1
(MSP1) and apical membrane antigen 1 (AMA1), have been
intensively studied as promising vaccine candidates. These two
antigens are well conserved across all species of Plasmodium and
play important roles in erythrocyte invasion and blood-stage
growth. Several passive and active immunization studies have
indicated that both antigens elicit protective immune responses
and serve as targets for invasion-blocking antibodies [1,2,3].
MSP1 is synthesized as an approximately 200-kDa precursor
protein at the schizont stage and is further proteolytically cleaved
into a number of discrete products residing on the surface of the
merozoite that invades the erythrocyte [4]. After processing, the
C-terminal 19-kDa fragment (MSP119) remains on the merozoite
surface during erythrocyte invasion and therefore is an ideal target
for blocking parasite invasion into the erythrocyte [5]. Several
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13727studies have shown that immunization with the bacterially-
produced recombinant MSP119 with an adjuvant completely
protects mice against P. yoelii challenge [6,7,8]. The P. falciparum
MSP119 has been implicated as a target for protective immunity in
a large number of studies, including seroepidemiological studies of
naturally-acquired immunity, vaccination studies in non-human
primates and in vitro cultures [9]. In particular, antibodies to
MSP119, either affinity purified from immune human sera or
monoclonal or polyclonal experimental sera, are capable of
inhibiting parasite growth in vitro [10,11,12]. Recently, however,
the value of these in vitro assays has come into question because
cytophilic MSP119-specific antibodies appear to be more impor-
tant for controlling infection than previously thought [13,14] and
the protective efficacy of MSP119-based vaccines do not correlate
with anti-MSP119 antibody titers or in vitro parasite-inhibitory
activity in animal models [15].
AMA1, synthesized as a 60–80-kDa protein during schizogony,
is a microneme protein involved in merozoite invasion of
erythrocytes. AMA1 possesses a large N-terminal cysteine-rich
ectodomain, followed by a single transmembrane domain and a
short C-terminal cytoplasmic tail. The ectodomain has been
divided into three domains (I, II, and III) based on the disulfide
bond position [16,17] and the recent crystal structure [18].
Domain III binds to human erythrocytes [19] and serves as a
target for growth-inhibitory antibodies [20]. Immunization with
parasite-derived AMA1 and recombinant AMA1 induced signif-
icant levels of protection against P. yoelii challenge in mice [21] and
against P. falciparum challenge in Aotus monkeys [22], respectively.
Despite its promising potential, neither PfMSP119- nor PfAMA1-
based vaccine candidates have yet shown satisfactory outcomes in
human clinical trials. Discrepancies in the vaccine efficacies
observed between the P. yoelii model and human clinical trials still
remain problematic, although poor immunogenicity and genetic
polymorphisms are thought to be major obstacles for vaccine
development using these molecules [23,24,25,26].
We have recently developed a baculoviral-based vaccine (BBV)
expressing PyMSP119 on the surface of the viral envelope [27].
Adjuvant-free intranasal immunization with this vaccine induced
not only strong systemic humoral immune responses with high
titers of PyMSP119-specific antibody but also natural boosting of
PyMSP119-specific antibody responses shortly after challenge, and
conferred complete protection. As a next step, we have generated
a PfMSP119-BBV vaccine to address the possibility of its use in a
clinical setting. In the present study, we evaluated the protective
efficacies of a series of MSP119- and AMA1-BBVs against
challenge with transgenic P. berghei expressing PfMSP119 as well
as P. berghei in mice. Our results show that although immunization
with these BBVs induced high levels of antigen-specific antibody
titers, none of the immunized mice were protected against
challenge. In contrast, immunization with PyMSP119- and
PyAMA1-BBVs provided 100% and 40% protection against lethal
challenge with P. yoelii, respectively. These data suggest that P.
berghei possesses additional molecules and/or mechanisms that
circumvent the host’s immune responses to MSP119 and AMA1.
The present study provides important insights for malaria blood-
stage vaccine development using P. yoelii and P. berghei.
Materials and Methods
Ethics Statement
All care and handling of the animals was in accordance with the
Guidelines for Animal Care and Use prepared by Jichi Medical
University, following approval (ID: 09193) by the Jichi Medical
University Ethical Review Board.
Mice and parasites
Female BALB/c and C57/BL6 mice, 7 to 8 weeks of age at the
start of the experiments, were purchased from Nippon Clea
(Tokyo, Japan). P. berghei ANKA were used for challenge infection.
P. yoelii 17XL, a lethal murine malaria parasite, was kindly
provided by T. Tsuboi (Ehime University, Matsuyama, Japan). P.
falciparum 3D7 was kindly provided by K. Kita (The University of
Tokyo, Tokyo, Japan). Pb-PfM19 [28], transgenic P. berghei ANKA
expressing PfMSP119 in place of native PbMSP119, was kindly
provided by T. Koning-Ward (The Walter and Eliza Hall Institute
of Medical research, Parkville, Australia).
Recombinant baculovirus
For the construction of MSP119-expressing baculovirus transfer
vectors, the DNA sequence corresponding to amino acids
Asn1607–Asn1702 of PfMSP119 was amplified from P. falciparum
3D7 genomic DNA using the primer pair pPfMSP119-F1 (59-
GAATTCAACATTTCACAACACCAATGCGTAAAAAAAC-
39)/pPfMSP119-R1 (59-CCCGGGCGTTAGAGGAACTGCAG-
AAAATACCATCG-39). Similarly, the DNA sequence corre-
sponding to amino acids Gly1672-Ser1767 of PbMSP119 was
amplified from P. berghei ANKA genomic DNA using the primer
pair pPbMSP119-F1 (59-GAATTCGGTATAGACCCTAAG-
CATGTATGT-39)/pPbMSP119-R1 (59-CCCGGGAGCTACA-
GAATACACCATCATAATATGC-39). Each of the resulting
PCR products was ligated into the EcoRI/SmaI sites of pBAC-
surf-PyMSP119 [27] to construct baculovirus transfer vectors.
For the construction of AMA1-expressing baculovirus transfer
vectors, the DNA sequences corresponding to amino acids
Asn53-Glu478 (domains I, II and III) and Glu380-Glu478 (domain
III) of PbAMA1 (PbAMA1-D123 and PbAMA1-D3, respectively)
were amplified from P. berghei ANKA genomic DNA
using the primer pairs pPbAMA1-F1 (59-GAATTCAATC-
CATGGGAAAAGTATACGGAAAAATAT-39)/pPbAMA1-R1
(59-CCCGGGCTTCTCTGGTTTGATGGGCTTTCATATG-
CAC-39) and pPbAMA1-F2 (59-GAATTCGAAGAGTTCGAA-
GAACAATTTCCTTGTGAT-39)/pPbAMA1-R1, respectively.
Similarly, the DNA sequences corresponding to amino acids
Ile52-Lys479 (domains I, II and III) and Glu380-Lys479 (domain
III) of PyAMA1 (PyAMA1-D123 and PyAMA1-D3, respectively)
were amplified from P. yoelii 17XL genomic DNA using the
primer pairs pPyAMA1-F1 (59-GAATTCAATCCATGGG-
ATAAATATATGGAAAAATATGAT-39)/pPyAMA1-R1 (59-
CCCGGGTTTTCTGGTTTGGGTTTTCATAGTCACCTA-
T-39) and pPyAMA1-F2 (59-GAATTCGAAGAAAATTTT-
CCTTGTGAAATATAT-39)/pPyAMA1-R1, respectively. Each
oftheresultingPCRproductswasligatedintotheEcoRI/SmaIsites
of pBACsurf-PyMSP119 [27] to construct baculovirus transfer
vectors. Recombinant baculoviruses, AcNPV-PfMSP119surf,
AcNPV-PbMSP119surf, AcNPV-PyAMA1-D123surf, AcNPV-
PyAMA1-D3surf, AcNPV-PbAMA1-D123surf, and AcNPV-
PbAMA1-D3surf were generated in Spodoptera frugiperda (Sf9) cells
byco-transfectionofthecorrespondingbaculovirustransfervector
with BacVector-2000 DNA (Novagen) according to the manufac-
turer’s protocol. AcNPV-PyMSP119surf has been described
previously [27]. Purification of baculovirus virions was per-
formed as described previously [29]. The purified baculovirus
particles were free of endotoxin (,0.01 endotoxin units/
10
9 pfu), as determined by an EndospecyH endotoxin mea-
surement kit (Seikagaku Co., Tokyo, Japan).
Recombinant proteins
The Pfmsp119, Pbmsp119, Pyama1-D3 and Pbama1-D3 genes were
excised from pBACsurf-PfMSP119, pBACsurf-PbMSP119, pBAC-
PbMSP1 Vaccine Ineffectiveness
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gestion with EcoRI and SmaI. Each of these DNA fragments was
cloned into the EcoR I/SmaI sites of pGEX-4T-1 (GE Healthcare
UK Limited, Buckinghamshire, UK). Recombinant PfMSP119,
PbMSP119, PyAMA1-D3 and PbAMA1-D3 created as GST
fusion proteins (termed GST-PfMSP119, GST-PbMSP119, GST-
PyAMA1-D3 and GST-PbAMA1-D3 respectively), were ex-
pressed in Escherichia coli and purified using GST affinity columns
(GE Healthcare UK Limited) as described previously [30]. GST-
PyMSP119 was used as an immunogen for vaccination and antigen
for ELISA as described previously [27]. These recombinant
proteins were recognized by P. yoelii or P. berghei-hyperimmune
sera, which were obtained from BALB/c mice that had recovered
from repeated infections of the corresponding parasite following
treatment with chloroquine as described previously [28]. A
recombinant MSP119 (yPfMSP119)o fP. falciparum, produced in
Saccharomyces cerevisiae, was obtained from MR4 (Manassas, VA).
We confirmed that the bacterially-produced GST-PfMSP119 and
yPfMSP119 proteins had the similar immunogenicity available in
ELISA’s using sera obtained from AcNPV-PfMSP119surf-immu-
nized mice and malaria-exposed individuals living in a hyperen-
demic area. These GST-fusion proteins were used as immunogens
for vaccination and antigens for ELISA. A recombinant MSP119
(yPyMSP119)o fP. yoelii 17XL, produced in S. cerevisiae, was
obtained from MR4, and used as an antigen for ELISA.
Immunoblotting and indirect immunofluorescence assay
(IFA)
For immunoblotting, protein samples were separated on a 6%
SDS-PAGE gel, transferred to Immobilon
TM Transfer Membrane
(Millipore, Bedford, MA). The membrane was treated either with
the anti-PfMSP119 mAb 5.2 (MR4, Manassas, VA), anti-gp64
mAb (BD Biosciences, Bedford, MA), or P. berghei-o rP. yoelii-
hyperimmune sera. Polypeptides recognized by the antibodies
were visualized by color development with 5-bromo-4-chloro-3-
indolylphosphate p-toluidine salt/nitroblue tetrazolium chloride
substrate (Invitrogen) following biotinylated anti-mouse IgG
secondary antibody (Vector Laboratories, Burlingame, CA) as
described previously [29]. Alternatively, polypeptides recognized
by the antibodies were detected with ECL
TM Western Blotting
Detection Reagents (GE Healthcare UK Ltd.) using an HRP-
conjugated goat anti-mouse IgG (H+L) secondary antibody (Bio-
Rad, Hercules, CA).
For IFA, erythrocytes infected with parasites were washed,
aliquoted onto multiwell slides, and fixed in 4% paraformaldehyde
or methanol/acetone (4:6) for 30 min. Sera were diluted 1:1,000
and incubated on the slide at room temperature for 1 h following
permeabilization with 1% Triton X in PBS. After washing, the
slides were incubated with fluorescein isothiocyanate (FITC)-
conjugated goat anti-mouse IgG for 1 h, washed, and covered
with a drop of VECTASHIELD
TM with DAPI (49 6-diamidion-2-
phenylindole) (Vector Laboratories). Bound antibodies were
detected using a BZ 9000 fluorescence microscope (Keyence,
Tokyo, Japan).
Immunization and challenge infections
Mice were immunized three times at 3-week intervals with
5610
7 pfu of BBV either by an intramuscular (i.m.) or intranasal
(i.n.) route as described previously [27]. As a comparative control,
mice were immunized intraperitoneally (i.p.) with 50 mg of GST-
PbMSP119, GST-PfMSP119 or GST-PyMSP119 in 2 mg of
aluminum hydroxide (ImjectH Alum, Pierce) three times at 3-
week intervals. For each route of immunization, 2 weeks after the
final immunization, sera were collected and mice were challenged
with 1,000 live parasite-infected red blood cells (pRBC) by
intravenous injection. The course of parasitemia was monitored
by microscopic examination of Giemsa-stained thin smears of tail
blood.
Enzyme-linked immunosorbent assay (ELISA) for
antibody titers
Sera obtained from immunized mice were collected by tail
bleeds 2 weeks after the final immunization prior to challenge. For
some mice, serum was also collected periodically after challenge.
For MSP119-specific antibody detection, pre-coated ELISA plates
with 100 ng/well GST-PfMSP119, GST-PbMSP119, GST-
PyMSP119, PyAMA1-D3, PbAMA1-D3, and yPyMSP119 were
incubated with serial dilutions of sera obtained from immunized
and control mice. MSP119- or AMA1D3-specific antibodies were
detected using HRP-conjugated goat anti-mouse IgG (H+L) (Bio-
Rad). The plates were developed with peroxidase substrate
solution [H2O2 and 2,29-azino-bis(3-ethylbenzothiazoline-6-sulfo-
nate)]. The optical density (OD) at 414 nm of each well was
measured using a plate reader. Endpoint titers were expressed as
the reciprocal of the highest sample dilution for which the OD was
equal or greater than the mean OD of non-immune control sera.
Infection and drug treatment
Groups of five mice were infected with P. yoelii XL or P. berghei
ANKA pRBC. When the parasitemia had reached 1–3%, mice
were treated i.m. on 3 consecutive days with 100 ml of 10 mg/ml
Artemether InjectionH (Kunming Pharmaceutical Corp., Kunm-
ing, China) dissolved in olive oil (Yoshida Pharmaceutical Corp.,
Tokyo, Japan). Four weeks after the completion of the infection
and drug cure regimen, mice were re-infected three times with
1,000 live pRBC of homologous parasite at 4-week intervals. Self-
cured mice were challenged with 1,000 live pRBC of heterologous
parasites (P. yoelii XL or P. berghei ANKA). The same experiment
was repeated. The course of parasitemia was monitored by
microscopic examination of Giemsa-stained thin smears of tail
blood.
Results
Construction of MSP119-BBV
Recently, we have developed a new PyMSP119-BBV (AcNPV-
PyMSP119surf) that displays PyMSP119 on the surface of the
baculoviral envelope. Adjuvant-free intranasal immunization with
this vaccine induced strong systemic humoral immune responses
with high titers of PyMSP119-specific antibody, naturally boosted
the PyMSP119-specific antibody response a short time after
infection, and allowed 100% of mice to self-cure with very low
parasitemia [27]. To apply this baculoviral vaccine system to P.
falciparum MSP119 vaccine development, we generated AcNPV-
PfMSP119surf and AcNPV-PbMSP119surf (Figure 1A). Each
construct harbored a gene cassette that consisted of the gp64
signal sequence and the MSP119 gene fused to the N-terminus of
the AcNPV major envelope protein gp64. Expression of these gene
cassettes was driven by the polyhedrin promoter. Thus these BBVs
were designed to express MSP119 on the viral envelope as a gp64
fusion protein.
MSP119 fused to gp64 exhibits the three-dimensional
structure of the native MSP119 with correctly formed
disulfide bonds
Western blotting analysis shows that the anti-PfMSP119 mAb
5.2, which has previously been shown to recognize a conforma-
PbMSP1 Vaccine Ineffectiveness
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with relative molecular masses (Mr) of 75 and 85 kDa in the
presence of 2-ME (Figure 1B, lanes 1–2). Much stronger smear
bands with high Mr were seen in the absence of 2-ME, (lane 3),
indicating formation of oligomer complexes. P. berghei-hyperim-
mune serum reacted with a 75-kDa band corresponding to the
PbMSP119-gp64 fusion protein in the presence of 5% 2-ME.
Similar to the PfMSP119-gp64 fusion protein complex, strong
smear bands of PbMSP119-gp64 fusion protein with high Mr were
seen in the absence of 2-ME (lane 6). These results are consistent
with previous results showing that the PyMSP119-gp64 fusion
protein was susceptible to treatment with 2-ME as detected using
P. yoelii-hyperimmune serum (lanes 7–9) [27]. The anti-gp64 mAb
reacted with three MSP119-gp64 fusion proteins and endogenous
gp64 (lanes 10–12). The total intensity of endogenous gp64 plus
each MSP119-gp64 fusion protein band seems to be similar to that
of each smear band (lanes 3, 6 and 9) under the non-reducing
conditions. These results indicate that these three MSP119-gp64
fusion proteins form oligomer complexes not only with MSP119-
gp64 fusion protein but also endogenous gp64 on the virus
envelope and retain the three-dimensional structures of the native
MSP119 with correctly formed disulfide bonds.
Figure 1. Construction and expression analysis of MSP119-BBVs. (A) Schematic diagram of three MSP119-BBV genomes. MSP119 was
expressed as a MSP119-gp64 fusion protein under the control of the polyhedron promoter. Numbers indicate the amino acid positions of MSP119-
gp64 fusion protein and endogenous gp64 protein. pPolh, polyhedrin promoter; SP, the gp64 signal sequence; FLAG, the FLAG epitope tag; pgp64,
gp64 promoter. (B) Western blot analysis of MSP119-BBVs. AcNPV-PfMSP119surf (lanes 1, 2, 3 and 10), AcNPV-PbMSP119surf (lanes 4, 5, 6 and 11) and
AcNPV-PyMSP119surf (lanes 7, 8, 9 and 12) were treated with the loading buffer with 5% 2-ME (lanes 1, 4, 7, 10, 11 and 12), 0.5% 2-ME (lanes 2, 5 and
8) or without 2-ME (lanes 3, 6 and 9) and examined using the 5.2 mAb (lanes 1–3), P. berghei-hyperimmune serum (lanes 4–6), P. yoelii-hyperimmune
serum (lanes 7–9) and anti-gp64 mAb (lanes 10–12). Positions of MSP119-gp64 fusion protein and endogenous gp64 are shown at the right panel of
lanes 10–12. (C–H) Immunofluorescence patterns of sera obtained from mice immunized with three MSP119-BBVs on paraformaldehyde fixed
erythrocyte smears infected with P. falciparum (C–D), P. berghei (E–F) and P. yoelii (G–H). The smears were incubated with serum obtained from an
individual mouse immunized either with AcNPV-PfMSP119surf (C), AcNPV-PbMSP119surf (E) or AcNPV-PyMSP119surf (G), and antibody binding was
detected with secondary FITC-labeled antibody. Cell nuclei were visualized by DAPI staining on the corresponding smears (D, F and H). Scale bar,
10 mm.
doi:10.1371/journal.pone.0013727.g001
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AcNPV-PfMSP119surf did not confer protection against
Pb-PfMSP1 parasites
Both i.m. and i.n. immunization of BALB/c mice with AcNPV-
PfMSP119surf induced high titers of PfMSP119-specifc antibodies
(72,600619,300 and 167,000647,300, respectively) (Table 1,
EXP1). These immune sera strongly reacted with native PfMSP119
on P. falciparum schizonts with circumferential staining, character-
istic of an antigen present on the parasite surface (Figure 1C).
However, none of the immunized mice survived following
challenge with Pb-PfM19 parasites (transgenic P. berghei expressing
PfMSP119 in place of native PbMSP119). In accordance with our
previous study [27], the i.m. and i.n. immunization with AcNPV-
PyMSP119surf conferred 50% and 100% protection, respectively,
against P. yoelii challenge infection (Table 1, EXP2,G4-5).
Moreover, we and others have demonstrated that mice immunized
with E. coli-producing GST-PyMSP119 formulated in Freund’s or
alum adjuvant were protected against P. yoelii challenge infection.
While immunization with GST-PyMSP119 plus alum provided
70% protection against P. yoelii challenge infection, mice similarly
immunized with the same preparation of GST-PfMSP119 did not
survive following Pb-PfMSP1 parasite challenge, although the
immunization induced high titers of PfMSP119-specifc antibodies
(134,000628,600). Interestingly, one of 10 naı ¨ve mice self-cured
from high parasitemia following P. yoelii 17XL infection (Table 1,
EXP2 G1). We observed several monocytes actively phagocytosing
the parasites in the blood of the self-cured mouse (Supplementary
Figure S1). This is a very rare case because P. yoelii 17XL infection
of BALB/c mice was 100% lethal in our previous experiments.
The parasite clearance by phagocytosis may be due to the
activation of innate immunity during infection. It would be
interesting to address the triggers behind the induction of
protective immunity in a naı ¨ve mouse during infection.
To examine whether natural boosting of PfMSP-119-specific
antibodies was induced, the kinetics of the PfMSP119-specific
antibody titers and parasitemia during the course of infection were
determined. PfMSP119-specific antibodies induced by i.m. and i.n.
immunization with AcNPV-PfMSP119surf increased 2.7- and 4.2-
fold 11 days after challenge infection (Figure 2), indicating natural
boosting by challenge infection. However, the immunized groups
died with high levels of parasitemia and anemia but without signs
of cerebral malaria, which is similar to the non-immunized group.
AcNPV-PbMSP119surf was ineffective against P. berghei
To address the possibility that P. berghei is resistant to immune
responses to PbMSP119, AcNPV-PbMSP119surf was generated with
a construct similar to AcNPV-PyMSP119surf and AcNPV-
PfMSP119surf. As for the Pb-PfMSP1 parasites, none of the
BALB/c mice immunized i.m or i.n. with AcNPV-PbMSP119surf
survived following P. berghei challenge (Table 1, EXP3 G4–5),
although immunization induced high titers of PbMSP119-specifc
antibodies (103,000631,700 and 97,800649,800, respectively) with
strong reactivity against P. berghei mature schizonts (Figure 1E). In
addition, none of the BALB/c mice immunized with GST-
Table 1. Protective efficacies of MSP119-BBVs against challenge infection
a.
Vaccine (Challenge parasite) Mouse strain Route Anti-MSP119 titer
b mean±SE No. of protected mice/total no. (%)
EXP1 (Pb-PfM19)
G1: Non-immunized BALB/c - ND
c 0/5 (0)
G2: GST-PfMSP1+alum BALB/c i.p. 134,000628,600 0/5 (0)
G3: AcNPV-WT BALB/c i.m. ND 0/5 (0)
G4: AcNPV-PfMSP119surf BALB/c i.m. 72,600619,300 0/5 (0)
G5: AcNPV-PfMSP119surf BALB/c i.n. 167,000647,300 0/5 (0)
EXP2 (P. yoelii)
G1: Non-immunize BALB/c - ND 1/10 (10)
G2: GST-PyMSP119+alum BALB/c i.p. 171,0006138,000 7/10 (70)
G3: AcNPV-WT BALB/c i.m. ND 0/10 (0)
G4: AcNPV-PyMSP119surf BALB/c i.m. 159,000655,700 5/10 (50)
G5: AcNPV-PyMSP119surf BALB/c i.n. 126,000633,900 10/10 (100)
EXP3 (P. berghei)
G1: Non-immunize BALB/c - ND 0/5 (0)
G2: GST-PbMSP119+alum BALB/c i.p. 256,000655,000 0/10 (0)
G3: AcNPV-WT BALB/c i.m. ND 0/5 (0)
G4: AcNPV-PbMSP119surf BALB/c i.m. 103,000631,700 0/5 (0)
G5: AcNPV-PbMSP119surf BALB/c i.n. 97,800649,800 0/10 (0)
G6: Non-immunize C57/BL6 - ND 0/5 (0)
G7: AcNPV-WT C57/BL6 i.m. ND 0/5 (0)
G8: AcNPV-PbMSP119surf C57/BL6 i.m. 88,10068,590 0/5 (0)
aGroups of mice were immunized with MSP119-BBVs three times and challenged either with Pb-PfMSP19, P. yoelii or P. berghei following blood collection for ELISA.
bLevels of PfMSP119-, PyMSP119- and PbMSP119- specific IgG for EXP1, 2 and 3, respectively, were measured by ELISA.
cND, not detectable level (,500).
doi:10.1371/journal.pone.0013727.t001
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although the immunization induced high titers of PbMSP119-specifc
antibodies (256,000655,000). There is no difference in the course of
infection and survival time between the AcNPV-PbMSP119 and
non-immunized BALB/c groups (Supplementary Figure S2). Since
P. berghei ANKA infection of C57BL/6 mice, but not BALB/c mice,
has been shown to lead to ‘‘cerebral malaria’’ [32], it is important to
examine whether the vaccine efficacy and the course of infection are
different between BALB/c and C57BL/6 mice. All groups of
C57BL/6 mice infected with P. berghei ANKA (Table 1, EXP 3 G6–
8)died exhibitinglowparasitemia (,15%)8–10 daysafterchallenge,
which may be due to cerebral malaria (Supplementary Figure S2).
Similar to BALB/c mice, there is no difference in the course of
infection and survival time between AcNPV-PbMSP119 and non-
immunized B57BL/6 groups (Supplementary Figure S2). Thus
AcNPV-PbMSP119 did not contribute to any protective effect or
reduction of symptoms either in BALB/c or C57BL/6 mice,
indicating that P. berghei and Pb-PfM19 parasites circumvent
immune responses to MSP119-BBVs, which are effective for P. yoelii.
Construction and expression of AMA1-BBV
To compare the protective efficacies of another leading vaccine
candidate, AMA1, against P. yoelii and P. berghei, we generated two
kinds of PyAMA1- and PbAMA1-BBVs consisting of ectodomains
I-III or III alone (AcNPV-PyAMA1-D123surf, AcNPV-PyAMA1-
D3surf, AcNPV-PbAMA1-D123suf, and AcNPV-PbAMA1-
D3surf) (Figure 3A). Similar to MSP119-BBV, each construct
harbored a gene cassette that consisted of the gp64 signal sequence
and the target gene (PyAMA1-D123, PyAMA1-D3, PbAMA1-
D123, and PbAMA1-D3) fused to the N-terminus of the AcNPV
major envelope protein gp64. Western blotting analysis shows that
P. yoelii-hyperimmune serum reacted with the PyAMA1-D123-
and PyAMA1-D3-gp64 fusion proteins of AcNPV-PyAMA1-
D123suf and AcNPV-PyAMA1-D3surf with molecular weights
of 125 kDa and 95 kDa, respectively (Figure 3B, lanes 1 and 2).
Similar results were obtained with the PbAMA1-D123- and
PbAMA1-D3-gp64 fusion proteins of AcNPV-PbAMA1-D123suf
and AcNPV-PbAMA1-D3surf against P. berghei-hyperimmune
serum (lanes 3 and 4).
Protective efficacy of AMA1-BBV against challenge
infection
Intramuscular immunization of BALB/c mice with AcNPV-
PyAMA1-D123surf induced higher titers of PyAMA1-specifc
antibodies than i.n. immunization (i.m. vs. i.n. =20,90068,700
vs. 7,20062,470) (Table 2, EXP4 G2–3). Both immune sera
strongly reacted with native PyAMA1 on P. yoelii mature schizonts,
which is consistent with AMA1 localization on the surface of
merozoites (Figure 3C and E). In the i.m. AcNPV-PyAMA1-
D123surf group, five of 10 mice (50%) survived P. yoelii challenge
infection, whereas two of 10 mice (20%) survived challenge
infection in the i.n. AcNPV-PyAMA1-D123surf group. Although
both i.m. and i.n. immunization with AcNPV-PyAMA1-D3surf
induced similar levels of PyAMA1-specifc antibodies, all immu-
nized mice died following P. yoelii challenge infection, indicating
that PyAMA1-D123 induced partial protective immune responses,
but not PyAMA1-D3. In spite of correct folding on the surface of
the baculoviral virion, PyAMA1-D3 may not have any neutral-
izing epitopes that protect against P. yoelii infection. Consistent
with our previous study [27], the i.m. immunization (40%
protection) with AcNPV-PyMSP119surf was less effective than
the i.n. immunization (100% protection). Interestingly, when mice
were immunized i.m. with a mixture of AcNPV-PyMSP119surf
and AcNPV-PyAMA1-D123surf, all mice induced PyMSP119-
and PyAMA1-specific antibodies and survived P. yoelii challenge
infection with less severe infection outcomes and low peak
parasitemia, indicating a synergistic effect of PyMSP119 and
PyAMA1 on protection. In contrast to the P. yoelii model, two
PbAMA1-BBVs (AcNPV-PbAMA1-D123surf and AcNPV-
PbAMA1-D3surf) failed to protect against P. berghei challenge,
although PbAMA1-specific antibodies, which can recognize P.
berghei schizonts (Figure 3G and I), were induced (Table 2, EXP5).
Naturally acquired protective immunity to P. berghei
confers resistance to P. yoelii, but not vice versa
While many studies have consistently shown that the ELISA
titer of MSP119- and AMA1-immunized mice correlates with
protective immunity against P. yoelii challenge, the corresponding
P. berghei vaccines failed to protect against P. berghei. Therefore, it
was of interest to determine the degree of heterologous immunity
occurring between P. yoelii and P. berghei. BALB/c mice infected
either with P. yoelii or P. berghei were drug-cured by three doses of
Artemether. This drug treatment regimen completely cleared
parasitemia so that no recurrence or recrudescence parasite
appeared. The self-cured mice were re-infected three times with
the homologous parasite. At the first challenge after drug
treatment, some mice developed low levels of parasitemia
(,10%) in both groups, and all self-cured within 7 days (data
Figure 2. Kinetics of PfMSP119-specific antibody titers and parasitemia during the course of infection. Groups of mice were non-
immunized or immunized either i.m. or i.n. with AcNPV-PfMSP119surf, and then challenged i.v. with 10
3 Pb-PfM19 pRBC. Parasitemia was monitored
daily 4 days after challenge and sera were collected periodically post-challenge to measure antibody titers. The bar chart indicates PfMSP119-specific
antibody titers on the left vertical axis. The line graph indicates the course of parasitemia (%) on the right vertical axis. (+), death.
doi:10.1371/journal.pone.0013727.g002
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third homologous challenges, indicating that mice naturally
acquired sterile protective immunity against homologous infection.
Subsequently, these mice were challenged with the heterologous
parasite. All of the self-cured mice from P. berghei completely
protected against P. yoelii with undetectable levels of parasitemia
(Table 3, EXP6 G1), indicating the acquisition of cross-resistance
to P. yoelii infection. In contrast, all the self-cured mice from P. yoelii
suffered from severe courses of P. berghei infection with high
maximum parasitemia levels (.70% parasitemia) and 100%
mortality (G2). Thus naturally acquired sterile immunity induced
by drug treatment and repeated P. berghei infection can persistently
protect mice against P. yoelii infection, but not vice versa.
Discussion
In the present study, we demonstrate that the two leading
malaria blood-stage vaccine candidate antigens, MSP119 and
AMA1, failed to protect against P. berghei and its transgenic
parasite challenge infection, although immunization with these
vaccines induced high levels of antigen-specific antibody titers, and
the immune sera strongly reacted with the blood-stage parasites.
Our previous study showed that immunization with AcNPV-
PyMSP119surf completely clears P. yoelii shortly after challenge by
a quick natural boosting response [27]. On the other hand,
immunization with the bacterially-produced GST-PyMSP119 plus
alum impairs P. yoelii growth at the time of infection by induced
PyMSP119-specific antibodies, resulting in a delay in the onset of a
patent parasitemia and protracted period of parasite inhibition
[6,33,34,35]. Therefore, these two vaccine formulas inducing
different protective immune responses are suitable immunogens to
investigate whether MSP119-specific immune responses could
confer protection or affect the course of infection in P. berghei
ANKA and its transgenic models. Since MSP119 is highly
structured on the surface of merozoites, folding into two epidermal
growth factor-like domains [36], development of MSP119-based
vaccines with its native three-dimensional structure would be
necessary to induce protective immune responses. This is similar to
Figure 3. Construction and expression analysis of AMA1-BBVs. (A) Schematic diagram of four AMA1-BBV genomes. AMA1 was expressed as
an AMA1-gp64 fusion protein under the control of the polyhedron promoter. Numbers indicate the amino acid positions of AMA1-gp64 fusion
protein and endogenous gp64 protein. pPolh, polyhedrin promoter; SP, the gp64 signal sequence; FLAG, the FLAG epitope tag; pgp64, gp64
promoter. (B) Western blot analysis of AMA1-BBVs. AcNPV-PyAMA1-D123surf (lane 1), AcNPV-PyAMA1-D3surf (lane 2), AcNPV-PbAMA1-D123surf (lane
3) and AcNPV-PbAMA1-D3surf (lane 4) were treated with the loading buffer containing 1% 2-ME and examined using P. yoelii-hyperimmune serum
(lanes 1 and 2), or P. berghei-hyperimmune serum (lanes 3 and 4). (C–J) Immunofluorescence patterns of sera obtained from mice immunized with
four AMA1-BBVs on methanol-acetone fixed smears of erythrocytes infected with P. yoelii (C and E) and P. berghei (G and I). The smears were
incubated with serum obtained from an individual mouse immunized either with AcNPV-PyAMA1-D123surf (C), AcNPV-PyAMA1-D3surf (E), AcNPV-
PbAMA1-D123surf (G) or AcNPV-PbAMA1-D3surf (I), and antibody binding was detected with a secondary FITC-labeled antibody. Cell nuclei were
visualized by DAPI staining on the corresponding smears (D, F, H and J). Scale bar, 10 mm.
doi:10.1371/journal.pone.0013727.g003
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are stabilized by disulfide bonds, as evidenced by the loss of
conformational mAb and hyperimmune IgG binding, respectively,
in immunoblots with reduced MSP119-BBVs (Figure 1B). Addi-
tional evidence of the correct structure includes the induction of
IFA-reactive antibodies (Figures 2C–H). In the P. berghei transgenic
parasite model, although the AcNPV-PfMSP119surf group elicited
natural boosting of vaccine-induced PfMSP119-specific antibody
responses during infection, there was no significant reduction of
parasitemia or prolonging of survival time compared to non-
immunized groups. Similarly, neither PbMSP119- nor PbAMA1-
BBV was effective against P. berghei. In addition, the bacterially-
produced GST-PbMSP119 protein with alum adjuvant conferred
no protection. Thus P. berghei and its transgenic parasites
completely circumvent immune responses induced by MSP119-
and AMA1-based vaccines.
One possible mechanism by which the growth of P. berghei
cannot be controlled by high levels of PbMSP119- or PbAMA1-
specific antibodies is that P. berghei possesses additional molecules
and/or mechanisms other than MSP119 and AMA1 for erythro-
cyte invasion that are lacking in P. yoelii. In support of this, we
found that when mice self-cured from P. berghei infection by drug
treatment and subsequent P. berghei re-infections, they naturally
acquired sterile immunity against P. yoelii as well as P. berghei, but
not vice versa. This is consistent with a previous report that
protective cross-immunity operates only in one direction (P.
bergheiRP. yoelii) since mice immunized with a formalin-fixed
blood-stage P. yoelii were fully susceptible to P. berghei [37]. P.
falciparum has been shown to have a number of invasion pathways
and to be capable of entering erythrocytes by sialic acid-dependent
and -independent pathways [38]. While no such parallel invasion
pathways have been described for rodent malaria parasites, it is
possible that the multiplicity of merozoite surface proteins in P.
berghei may reflect involvement in alternative pathways of invasion.
Although a transgenic P. berghei line expressing PyMSP119 in place
of native PbMSP119 would be a good model to address this
possibility, we have failed to generate the transgenic line using
similar methodology for the construction of Pb-PfM19 [28],
suggesting that PbMSP119 and PfMSP119 share similar functions
essential for growth and/or invasion, but not with PyMSP119.
Another possible mechanism is that P. berghei infection may
impair antibody-dependent cellular inhibition of parasite growth.
We have previously demonstrated that a genetically engineered
bispecific single-chain antibody targeted to human CD3 and
PfMSP119 promotes merozoite phagocytosis and growth inhibition
in in vitro P. falciparum culture through cooperation with T cells and
monocytes [39]. Evidence has been accumulated to suggest that
antibody action via Fc interaction with monocytes/macrophages
plays an important role in protective immunity against blood-stage
parasites [14,40,41]. In the case of the P. yoelii model, MSP119-
and AMA1-specific antibodies may effectively function in the
parasite killing by cooperation with monocytes/macrophages.
However, P. berghei infection may strongly suppress monocyte/
Table 2. Protective efficacies of AMA1-BBVs against challenge infection
a.
Vaccine (Challenge parasite) Route
Anti-AMA1 D3 antibody
titer
c mean±SE
Anti-MSP119 antibody
titer
c mean±SE
No. of protected
mice/total no. (%)
EXP4 (P. yoelii)
G1: Non-immunized - ND
d ND 0/5 (0)
G2: AcNPV-PyAMA1-D123surf i.m. 20,90068,700 ND 5/10 (50)
G3: AcNPV-PyAMA1-D123surf i.n. 7,20062,470 ND 2/10 (20)
G4: AcNPV-PyAMA1-D3surf i.m. 26,10066,350 ND 0/5 (0)
G5: AcNPV-PyAMA1-D3surf i.n. 12,30062,450 ND 0/5 (0)
G6: AcNPV-PyMSP119surf i.m. ND 70,800611,210 2/5 (40)
G7
b: AcNPV-PyAMA1-D123surf
+ AcNPV-PyMSP119surf
i.m. 15,20065,800 94,600615,720 5/5 (100)
EXP5 (P. berghei)
G1: Non-immunized - ND ND 0/5 (0)
G2: AcNPV-PbAMA1-D123surf i.m. 9,80063,010 ND 0/5 (0)
G3: AcNPV-PbAMA1-D3surf i.m. 16,90065,310 ND 0/5 (0)
aGroups of BALB/c mice were immunized with AMA1-BBVs three times and challenged either with P. yoelii or P. berghei following blood collection for ELISA.
bThe two BBVs (AcNPV-PyAMA1-D123surf and AcNPV-PyMSP119surf) were mixed (2.5610
7 pfu each) and used for immunization.
cLevels of PyAMA1D3 and PyMSP119- specific IgGs and PbAMA1D3 and PbMSP119- specific IgGs for EXP4 and 5, respectively, were measured by ELISA.
dND, not detectable level (,500).
doi:10.1371/journal.pone.0013727.t002
Table 3. Protective efficacies against heterologous challenge
following drug treatment and 3 homologous re-infections
a.
Group
Parasite used for
drug treatment
and re-infection
Parasite used for
heterologous
challenge
No. of protected
mice/total no. (%)
EXP6
G1 Pb
b Py 10/10 (100)
G2 Py
c Pb 0/10 (0)
G3 NT
d Pb 0/5 (0)
G4 NT Py 0/5 (0)
aP. berghei-o rP. yoelii-infected BALB/c mice were treated with ArtemetherH.
The drug-cured mice were re-infected three times with homologous parasites
at 4-week intervals. All mice survived these re-infections. The self-cured mice
were then challenged with heterologous parasites.
bPb, P. berghei ANKA.
cPy, P. yoelii 17XL.
dNT, neither drug-treatment nor infection.
doi:10.1371/journal.pone.0013727.t003
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AMA1-specific antibodies. If P. falciparum uses mechanisms similar
to those utilized by P. berghei to circumvent MSP119- and AMA1-
based vaccine properties, P. berghei rather than P. yoelii would be a
more useful model to identify and evaluate new blood-stage
vaccine candidate antigens for P. falciparum.
Recently, P. berghei has been genetically engineered to express
representative vaccine candidate antigens (e.g., PfMSP119,
PfAMA1, PfCSP, Pfs25 and Pvs25) from the human malaria
parasites, P. falciparum and P. vivax [28,42,43,44,45]. These
transgenic P. berghei parasites provide great potential to investigate
the protective efficacies of vaccine candidates against the human
malaria parasites in vivo. Very recently, we have shown that
transmission blocking vaccines using the BBV system can induce a
remarkable reduction of malaria transmission to mosquitoes,
directly evaluated by immunization of mice following challenge
with Pfs25- or Pvs25-expressing P. berghei [46,47]. Although P.
berghei transgenic parasites expressing PfMSP119 and PfAMA1
have been used to evaluate the inhibitory effects on parasite
growth in vitro and through passive immunization [15,28,48], in vivo
challenge experiments following active immunization have not
been reported. Unlike P. yoelii, P. berghei has not been used for the
evaluation of vaccine efficacy against blood-stage parasites,
although the parasite has been well-studied not only for pre-
erythrocytic vaccine development but also a cerebral malaria
model [49]. To date, the usefulness of the transgenic P. berghei
model for evaluating protective efficacies of blood-stage antigens
remains unclear. In the present study, we were unable to show the
usefulness of PfMSP119-BBV as a promising malaria vaccine
candidate using the transgenic P. berghei, although a similar
construct of PyMSP119-BBV provided 100% protection in the P.
yoelii model [27]. We still cannot exclude the possibility that the
absence of protection induced by the PfMSP119 vaccine
formulations is due to qualitative differences between the
PyMSP119 and PfMSP119 vaccine formulations used here, rather
than differences in parasite susceptibility to anti-MSP119 respons-
es, although western blot and immunologiocal analyses show that
the three MSP119-gp64 fusion proteins as well as GST- MSP119
proteins were expressed at quantitatively similar levels and
immunization with these proteins induced high titers of MSP119-
specific antibodies with strong reactivity against mature schizonts
of the corresponding parasites. Further experiments using
PfMSP1-based vaccines with GMP level, which have been
evaluated in human clinical trials, would be needed to investigate
the susceptibility of Pb-PfMSP119 to anti-PfMSP119 responses.
Our results provide important insights for malaria blood-stage
vaccine development using P. yoelii and P. berghei and highlight the
need to deeply investigate the relationship between rodent and
human parasites. Obviously, it is important to elucidate the
discrepancy in the vaccine efficacies observed between the P. yoelii
model and human clinical trials. A better understanding of the
precise relationship between rodent and human parasites should
lead to a transfer of information from transgenic P. berghei to
human vaccine development prior to human clinical settings.
Supporting Information
Figure S1 Photomicrographs of Giemsa-stained thin blood
smears of the self-cured mouse. Ten non-immunized mice were
infected with P. yoelii 17XL-pRBC by i.v. injection. The course of
parasitemia was monitored daily from 4 days post-challenge by
microscopic examination of Giemsa-stained thin blood smears
obtained from tail bleeds. One of these mice self-cured from high
parasitemia of P. yoelii infection. The mouse cleared the parasites
21 days after challenge. The photomicrographs of the self-cured
mouse were taken at 19, 21 and 24 days after challenge. Arrows
indicate malaria pigment in monocytes phagocytosing the
parasites. Original magnification, 61,000.
Found at: doi:10.1371/journal.pone.0013727.s001 (6.18 MB TIF)
Figure S2 The course of parasitemia. BALB/c and C57BL/6
mice were immunized i.m. with AcNPV-PbMSP119surf or
AcNPV-WT and challenged i.v. with 10
3 P. berghei-pRBC.
Parasitemia was monitored daily from 5 days post-challenge. All
groups of BALB/c and C57BL/6 mice died 18 and 10 days after
challenge, respectively. Data (mean A ˆ6SD) are from the BALB/c
(EXP3 G 1, 3 and 4) and C57BL/6 (EXP3 G6–8) shown in
Table 1. closed triangle, non-immunized; open square, AcNPV-
WT; closed circle, AcNPV-PbMSP119surf.
Found at: doi:10.1371/journal.pone.0013727.s002 (6.11 MB TIF)
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